Michael Barry

Michael Barry

Biosimilar drugs offer a savings opportunity that we must take

Biosimilar drugs offer a savings opportunity that we must take

A dramatic increase in the prescribing of cheaper biosimilar medicines is required to enable us to afford costly new cancer and other therapies

The hard questions about new mediocre cancer drugs

The hard questions about new mediocre cancer drugs

Spending millions on drugs with limited benefits and a finite budget costs other patients

Pharma industry has no role in the education of doctors

Pharma industry has no role in the education of doctors

In careers spanning decades and with new medicines constantly coming on-stream, most GPs never get tested on their prescribing skills or receive unbiased advice on drugs

Big Pharma’s unhealthy reach

Big Pharma’s unhealthy reach

There is no such thing as a free lunch and, as usual, the taxpayer picks up the bill